Sanofi reports news as a global biopharmaceutical issuer with American depositary shares traded under SNY. Company updates center on medicines and vaccines built around immunology, specialty care, rare diseases, diabetes, respiratory disease and infectious-disease prevention, including recurring developments for products such as Dupixent, BEYFORTUS, insulins and pipeline candidates.
Sanofi news also covers clinical and regulatory milestones, collaborations with biotechnology and diagnostics partners, patient-access programs, community health initiatives, leadership changes and capital-allocation actions. As a foreign issuer, updates may reflect both parent-company announcements and ADR-related public-company disclosures.
Sanofi announced that the FDA has updated the label for FLUBLOK (Influenza Vaccine) to include data from a new safety study involving pregnant individuals 18 years and older. The study, involving over 48,000 pregnant individuals across multiple flu seasons, demonstrated that FLUBLOK safety is consistent with a standard-dose flu vaccine and pregnancy-related outcomes in the general population.
Key findings include:
- No increased risk of pregnancy, birth or neonatal/infant outcomes compared to standard-dose flu vaccine
- Similar rates of pregnancy outcomes between FLUBLOK and standard-dose vaccine groups
- Comparable birth and neonatal/infant outcomes between the two groups
The CDC, ACIP, and ACOG recommend flu vaccination for pregnant individuals due to their higher risk for severe illness and complications from flu.
Sanofi is shipping BEYFORTUS (nirsevimab-alip) in the US to protect babies against RSV disease. The company aims to provide access for every eligible baby, with a new FDA-approved manufacturing line expanding capacity to meet demand. BEYFORTUS is the first long-acting monoclonal antibody approved for RSV prevention in newborns and infants up to 24 months old.
Sanofi has collaborated with the White House, CDC, and FDA to ensure wide availability. The company has launched a Reservation Program for private healthcare providers and is working with AstraZeneca to build inventory for current and future seasons. Another filling line is expected to provide doses for the 2024/2025 season, further increasing production capacity.
Sanofi has entered an exclusive licensing agreement with RadioMedix and Orano Med for AlphaMedixTM, a late-stage targeted alpha therapy (TAT) project for treating neuroendocrine tumors (NETs). AlphaMedixTM has received Breakthrough Therapy Designation from the FDA for gastroenteropancreatic NETs. Phase 1 and 2 clinical studies showed a 62.5% durable response rate. Under the agreement, Sanofi will handle global commercialization, while Orano Med will manage manufacturing. RadioMedix and Orano Med will receive a €100 million upfront payment and up to €220 million in sales milestones, plus tiered royalties. This collaboration aligns with Sanofi's focus on oncology innovation and rare cancers.
Sanofi has begun shipping influenza vaccines across the U.S. for the 2024/25 flu season, starting on July 10, with shipments continuing through October. These vaccines, including Fluzone High-Dose, Flublok, and Fluzone, are designed to protect against three strains of influenza identified as the most likely to cause illness this season. Sanofi emphasizes the importance of flu vaccination to reduce risks such as pneumonia and cardiac events, especially in vulnerable populations. The company, a leader in global vaccine distribution, aims to support fall immunization campaigns by supplying healthcare providers, pharmacies, and other immunizers.
I-Mab (NASDAQ: IMAB) has announced the appointment of Dr. Phillip Dennis as Chief Medical Officer, effective June 17, 2024. Dr. Dennis will lead I-Mab's global clinical development and join the Executive Leadership Team. With two decades of oncology drug development experience, including key roles at Sanofi and AstraZeneca, Dr. Dennis brings significant expertise. His appointment aims to advance I-Mab's clinical pipeline, particularly for treatments like uliledlimab, givastomig, and ragistomig. Before his industry roles, Dr. Dennis was a professor at Johns Hopkins University and a senior investigator at the US National Cancer Institute.
Novavax reported its financial results and operational highlights for Q1 2024, including a co-exclusive licensing agreement with Sanofi for COVID-19 vaccines, a Phase 3 trial for a combination flu-COVID-19 vaccine, and a standalone influenza vaccine. The agreement holds potential multi-billion dollar revenue opportunities for Novavax, including upfront payments, equity investments, milestones, and royalties. Novavax also reduced liabilities by $831 million and achieved $94 million in revenue for Q1 2024. The company's financial position improved, with reduced losses and cash reserves of $496 million as of March 31, 2023.
Novavax and Sanofi have entered into a co-exclusive licensing agreement to co-commercialize a protein-based COVID-19 vaccine and develop novel COVID-19-Influenza combination vaccines. The agreement provides broader access to the vaccine from 2025 onwards and includes a cash and equity investment of approximately $1.2 billion for Novavax. This collaboration aims to accelerate the development of a combination product based on authorized vaccines for enhanced convenience and protection.
Summary not available.
Summary not available.
Summary not available.